PDCD1 and hepatocellular carcinoma: In a small cohort of 21 patients with advanced stage HCC, responders to nivolumab or pembrolizumab had elevated PD-1 expression on intratumoral CD8 T cells while those with tumor progression had elevated expression on circulating T cells [33].